Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 362

1.

Modeling and simulation of the modified Rankin Scale and National Institutes of Health Stroke Scale neurological endpoints in intracerebral hemorrhage.

Schoemaker R, Nayak S, Harnisch LO, Karlsson MO; VISTA-ICH Collaboration.

J Pharmacokinet Pharmacodyn. 2019 Aug 29. doi: 10.1007/s10928-019-09653-4. [Epub ahead of print]

PMID:
31468269
2.

Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients.

Abrantes JA, Solms A, Garmann D, Nielsen EI, Jönsson S, Karlsson MO.

Haematologica. 2019 Aug 1. pii: haematol.2019.217133. doi: 10.3324/haematol.2019.217133. [Epub ahead of print]

3.

Relating nicotine plasma concentration to momentary craving across four nicotine replacement therapy formulations.

Germovsek E, Hansson A, Kjellsson MC, Perez Ruixo JJ, Westin Å, Soons PA, Vermeulen A, Karlsson MO.

Clin Pharmacol Ther. 2019 Jul 29. doi: 10.1002/cpt.1595. [Epub ahead of print]

PMID:
31355455
4.

Item Response Model Adaptation for Analyzing Data from Different Versions of Parkinson's Disease Rating Scales.

Gottipati G, Berges AC, Yang S, Chen C, Karlsson MO, Plan EL.

Pharm Res. 2019 Jul 17;36(9):135. doi: 10.1007/s11095-019-2668-6.

5.

Sensitivity of Pegfilgrastim Pharmacokinetic and Pharmacodynamic Parameters to Product Differences in Similarity Studies.

Brekkan A, Lopez-Lazaro L, Plan EL, Nyberg J, Kankanwadi S, Karlsson MO.

AAPS J. 2019 Jul 8;21(5):85. doi: 10.1208/s12248-019-0349-3.

6.

A Bounded Integer Model for Rating and Composite Scale Data.

Wellhagen GJ, Kjellsson MC, Karlsson MO.

AAPS J. 2019 Jun 6;21(4):74. doi: 10.1208/s12248-019-0343-9.

7.

A Novel Method for Analysing Frequent Observations from Questionnaires in Order to Model Patient-Reported Outcomes: Application to EXACT® Daily Diary Data from COPD Patients.

Germovsek E, Ambery C, Yang S, Beerahee M, Karlsson MO, Plan EL.

AAPS J. 2019 Apr 26;21(4):60. doi: 10.1208/s12248-019-0319-9.

8.

Translation Between Two Models; Application with Integrated Glucose Homeostasis Models.

Ibrahim MMA, Largajolli A, Kjellsson MC, Karlsson MO.

Pharm Res. 2019 Apr 17;36(6):86. doi: 10.1007/s11095-019-2592-9.

PMID:
31001701
9.

The integrated glucose insulin minimal model: An improved version.

Ibrahim MMA, Largajolli A, Karlsson MO, Kjellsson MC.

Eur J Pharm Sci. 2019 Jun 15;134:7-19. doi: 10.1016/j.ejps.2019.04.010. Epub 2019 Apr 9.

PMID:
30978382
10.

Development of visual predictive checks accounting for multimodal parameter distributions in mixture models.

Arshad U, Chasseloup E, Nordgren R, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2019 Jun;46(3):241-250. doi: 10.1007/s10928-019-09632-9. Epub 2019 Apr 9.

11.

Variability Attribution for Automated Model Building.

Ibrahim MMA, Nordgren R, Kjellsson MC, Karlsson MO.

AAPS J. 2019 Mar 8;21(3):37. doi: 10.1208/s12248-019-0310-5.

12.

Model-Based Conditional Weighted Residuals Analysis for Structural Model Assessment.

Ibrahim MMA, Ueckert S, Freiberga S, Kjellsson MC, Karlsson MO.

AAPS J. 2019 Feb 27;21(3):34. doi: 10.1208/s12248-019-0305-2.

13.

A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6.

Thorsted A, Bouchene S, Tano E, Castegren M, Lipcsey M, Sjölin J, Karlsson MO, Friberg LE, Nielsen EI.

PLoS One. 2019 Feb 21;14(2):e0211981. doi: 10.1371/journal.pone.0211981. eCollection 2019.

14.

Handling interoccasion variability in model-based dose individualization using therapeutic drug monitoring data.

Abrantes JA, Jönsson S, Karlsson MO, Nielsen EI.

Br J Clin Pharmacol. 2019 Jun;85(6):1326-1336. doi: 10.1111/bcp.13901. Epub 2019 Apr 29.

PMID:
30767254
15.

Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling.

Schalkwijk S, Ter Heine R, Colbers A, Capparelli E, Best BM, Cressey TR, Greupink R, Russel FGM, Moltó J, Mirochnick M, Karlsson MO, Burger DM.

J Antimicrob Chemother. 2019 May 1;74(5):1348-1356. doi: 10.1093/jac/dky567.

PMID:
30715324
16.

Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib.

Niebecker R, Maas H, Staab A, Freiwald M, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2019 Apr;8(4):230-239. doi: 10.1002/psp4.12384. Epub 2019 Feb 27.

17.

Population pharmacokinetics of oral ivermectin in venous plasma and dried blood spots in healthy volunteers.

Duthaler U, Suenderhauf C, Karlsson MO, Hussner J, Meyer Zu Schwabedissen H, Krähenbühl S, Hammann F.

Br J Clin Pharmacol. 2019 Mar;85(3):626-633. doi: 10.1111/bcp.13840. Epub 2019 Jan 24.

PMID:
30566757
18.

A Population Pharmacokinetic-Pharmacodynamic Model of Pegfilgrastim.

Brekkan A, Lopez-Lazaro L, Yngman G, Plan EL, Acharya C, Hooker AC, Kankanwadi S, Karlsson MO.

AAPS J. 2018 Aug 15;20(5):91. doi: 10.1208/s12248-018-0249-y.

PMID:
30112626
19.

Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans.

Guiastrennec B, Sonne DP, Bergstrand M, Vilsbøll T, Knop FK, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):603-612. doi: 10.1002/psp4.12325. Epub 2018 Aug 12.

20.

Correction to: The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.

Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A.

Clin Pharmacokinet. 2019 Mar;58(3):401. doi: 10.1007/s40262-018-0706-x.

PMID:
30066294
21.

Population Pharmacokinetics of Artemether, Dihydroartemisinin, and Lumefantrine in Rwandese Pregnant Women Treated for Uncomplicated Plasmodium falciparum Malaria.

Lohy Das J, Rulisa S, de Vries PJ, Mens PF, Kaligirwa N, Agaba S, Tarning J, Karlsson MO, Dorlo TPC.

Antimicrob Agents Chemother. 2018 Sep 24;62(10). pii: e00518-18. doi: 10.1128/AAC.00518-18. Print 2018 Oct.

22.

The Clinical Pharmacology of Cladribine Tablets for the Treatment of Relapsing Multiple Sclerosis.

Hermann R, Karlsson MO, Novakovic AM, Terranova N, Fluck M, Munafo A.

Clin Pharmacokinet. 2019 Mar;58(3):283-297. doi: 10.1007/s40262-018-0695-9. Review. Erratum in: Clin Pharmacokinet. 2018 Aug 1;:.

23.

Model-Based Residual Post-Processing for Residual Model Identification.

Ibrahim MMA, Nordgren R, Kjellsson MC, Karlsson MO.

AAPS J. 2018 Jul 2;20(5):81. doi: 10.1208/s12248-018-0240-7.

PMID:
29968184
24.

Reduced and optimized trial designs for drugs described by a target mediated drug disposition model.

Brekkan A, Jönsson S, Karlsson MO, Hooker AC.

J Pharmacokinet Pharmacodyn. 2018 Aug;45(4):637-647. doi: 10.1007/s10928-018-9594-9. Epub 2018 Jun 8.

25.

Pharmacometric Analysis of the Relationship Between Absolute Lymphocyte Count and Expanded Disability Status Scale and Relapse Rate, Efficacy End Points, in Multiple Sclerosis Trials.

Novakovic AM, Thorsted A, Schindler E, Jönsson S, Munafo A, Karlsson MO.

J Clin Pharmacol. 2018 Oct;58(10):1284-1294. doi: 10.1002/jcph.1136. Epub 2018 May 10.

PMID:
29746722
26.

Study Design Selection in Early Clinical Anti-Hyperglycemic Drug Development: A Simulation Study of Glucose Tolerance Tests.

Ibrahim MMA, Ghadzi SMS, Kjellsson MC, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2018 Jul;7(7):432-441. doi: 10.1002/psp4.12302. Epub 2018 May 6. Erratum in: CPT Pharmacometrics Syst Pharmacol. 2019 Jul;8(7):520.

27.

Plasma and CSF pharmacokinetics of meropenem in neonates and young infants: results from the NeoMero studies.

Germovsek E, Lutsar I, Kipper K, Karlsson MO, Planche T, Chazallon C, Meyer L, Trafojer UMT, Metsvaht T, Fournier I, Sharland M, Heath P, Standing JF; NeoMero Consortium .

J Antimicrob Chemother. 2018 Jul 1;73(7):1908-1916. doi: 10.1093/jac/dky128.

28.

A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory.

Schindler E, Friberg LE, Lum BL, Wang B, Quartino A, Li C, Girish S, Jin JY, Karlsson MO.

Pharm Res. 2018 Apr 19;35(6):122. doi: 10.1007/s11095-018-2403-8.

29.

A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat.

Bouchene S, Marchand S, Couet W, Friberg LE, Gobin P, Lamarche I, Grégoire N, Björkman S, Karlsson MO.

Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):407-422. doi: 10.1111/bcpt.13026. Epub 2018 Jun 8.

PMID:
29665289
30.

Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Pierrillas PB, Fouliard S, Chenel M, Hooker AC, Friberg LE, Karlsson MO.

AAPS J. 2018 Mar 27;20(3):55. doi: 10.1208/s12248-018-0218-5.

PMID:
29589158
31.

Comparison of Power, Prognosis, and Extrapolation Properties of Four Population Pharmacodynamic Models of HbA1c for Type 2 Diabetes.

Wellhagen GJ, Karlsson MO, Kjellsson MC.

CPT Pharmacometrics Syst Pharmacol. 2018 May;7(5):331-341. doi: 10.1002/psp4.12290. Epub 2018 Mar 25.

32.

Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar.

Lohy Das JP, Kyaw MP, Nyunt MH, Chit K, Aye KH, Aye MM, Karlsson MO, Bergstrand M, Tarning J.

Malar J. 2018 Mar 23;17(1):126. doi: 10.1186/s12936-018-2278-5.

33.

Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Pierrillas PB, Fouliard S, Chenel M, Hooker AC, Friberg LE, Karlsson MO.

AAPS J. 2018 Mar 7;20(2):39. doi: 10.1208/s12248-018-0206-9. Erratum in: AAPS J. 2018 Mar 27;20(3):55.

PMID:
29516207
34.

A mechanism-based pharmacokinetic model of fenofibrate for explaining increased drug absorption after food consumption.

Back HM, Song B, Pradhan S, Chae JW, Han N, Kang W, Chang MJ, Zheng J, Kwon KI, Karlsson MO, Yun HY.

BMC Pharmacol Toxicol. 2018 Jan 25;19(1):4. doi: 10.1186/s40360-018-0194-5.

35.

Suboptimal Antituberculosis Drug Concentrations and Outcomes in Small and HIV-Coinfected Children in India: Recommendations for Dose Modifications.

Guiastrennec B, Ramachandran G, Karlsson MO, Kumar AKH, Bhavani PK, Gangadevi NP, Swaminathan S, Gupta A, Dooley KE, Savic RM.

Clin Pharmacol Ther. 2018 Oct;104(4):733-741. doi: 10.1002/cpt.987. Epub 2018 Feb 2.

36.

The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.

Netterberg I, Karlsson MO, Nielsen EI, Quartino AL, Lindman H, Friberg LE.

Br J Clin Pharmacol. 2018 Mar;84(3):490-500. doi: 10.1111/bcp.13477. Epub 2018 Jan 18.

37.

Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB.

Svensson EM, Karlsson MO.

J Antimicrob Chemother. 2017 Dec 1;72(12):3398-3405. doi: 10.1093/jac/dkx317.

38.

Visceral leishmaniasis relapse hazard is linked to reduced miltefosine exposure in patients from Eastern Africa: a population pharmacokinetic/pharmacodynamic study.

Dorlo TPC, Kip AE, Younis BM, Ellis SJ, Alves F, Beijnen JH, Njenga S, Kirigi G, Hailu A, Olobo J, Musa AM, Balasegaram M, Wasunna M, Karlsson MO, Khalil EAG.

J Antimicrob Chemother. 2017 Nov 1;72(11):3131-3140. doi: 10.1093/jac/dkx283.

39.

Model-Based Interspecies Scaling of Glucose Homeostasis.

Alskär O, Karlsson MO, Kjellsson MC.

CPT Pharmacometrics Syst Pharmacol. 2017 Nov;6(11):778-786. doi: 10.1002/psp4.12247. Epub 2017 Sep 28.

40.

Population Pharmacokinetic and Pharmacodynamic Modeling of Artemisinin Resistance in Southeast Asia.

Lohy Das J, Dondorp AM, Nosten F, Phyo AP, Hanpithakpong W, Ringwald P, Lim P, White NJ, Karlsson MO, Bergstrand M, Tarning J.

AAPS J. 2017 Nov;19(6):1842-1854. doi: 10.1208/s12248-017-0141-1. Epub 2017 Sep 11.

PMID:
28895080
41.

An automated sampling importance resampling procedure for estimating parameter uncertainty.

Dosne AG, Bergstrand M, Karlsson MO.

J Pharmacokinet Pharmacodyn. 2017 Dec;44(6):509-520. doi: 10.1007/s10928-017-9542-0. Epub 2017 Sep 8.

42.

Evidence-Based Design of Fixed-Dose Combinations: Principles and Application to Pediatric Anti-Tuberculosis Therapy.

Svensson EM, Yngman G, Denti P, McIlleron H, Kjellsson MC, Karlsson MO.

Clin Pharmacokinet. 2018 May;57(5):591-599. doi: 10.1007/s40262-017-0577-6.

43.

Dose-Exposure-Response Relationship of the Investigational Anti-Interleukin-13 Monoclonal Antibody Tralokinumab in Patients With Severe, Uncontrolled Asthma.

Baverel PG, White N, Vicini P, Karlsson MO, Agoram B.

Clin Pharmacol Ther. 2018 May;103(5):826-835. doi: 10.1002/cpt.803. Epub 2017 Sep 28.

PMID:
28758192
44.

Model averaging for robust assessment of QT prolongation by concentration-response analysis.

Dosne AG, Bergstrand M, Karlsson MO, Renard D, Heimann G.

Stat Med. 2017 Oct 30;36(24):3844-3857. doi: 10.1002/sim.7395. Epub 2017 Jul 13.

PMID:
28703360
45.

Open innovation: Towards sharing of data, models and workflows.

Conrado DJ, Karlsson MO, Romero K, Sarr C, Wilkins JJ.

Eur J Pharm Sci. 2017 Nov 15;109S:S65-S71. doi: 10.1016/j.ejps.2017.06.035. Epub 2017 Jul 4. Review.

PMID:
28684136
46.

CORRIGENDUM: Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium.

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium.

Clin Pharmacol Ther. 2017 Jul;102(1):152. doi: 10.1002/cpt.725. No abstract available.

PMID:
30239993
47.

Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring.

Netterberg I, Nielsen EI, Friberg LE, Karlsson MO.

Cancer Chemother Pharmacol. 2017 Aug;80(2):343-353. doi: 10.1007/s00280-017-3366-x. Epub 2017 Jun 27.

48.

Model Description Language (MDL): A Standard for Modeling and Simulation.

Smith MK, Moodie SL, Bizzotto R, Blaudez E, Borella E, Carrara L, Chan P, Chenel M, Comets E, Gieschke R, Harling K, Harnisch L, Hartung N, Hooker AC, Karlsson MO, Kaye R, Kloft C, Kokash N, Lavielle M, Lestini G, Magni P, Mari A, Mentré F, Muselle C, Nordgren R, Nyberg HB, Parra-Guillén ZP, Pasotti L, Rode-Kristensen N, Sardu ML, Smith GR, Swat MJ, Terranova N, Yngman G, Yvon F, Holford N; DDMoRe consortium.

CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):647-650. doi: 10.1002/psp4.12222. Epub 2017 Jul 12. No abstract available.

49.

A Minimal Continuous-Time Markov Pharmacometric Model.

Schindler E, Karlsson MO.

AAPS J. 2017 Sep;19(5):1424-1435. doi: 10.1208/s12248-017-0109-1. Epub 2017 Jun 20.

PMID:
28634883
50.

Implications for Drug Characterization in Glucose Tolerance Tests Without Insulin: Simulation Study of Power and Predictions Using Model-Based Analysis.

Sheikh Ghadzi SM, Karlsson MO, Kjellsson MC.

CPT Pharmacometrics Syst Pharmacol. 2017 Oct;6(10):686-694. doi: 10.1002/psp4.12214. Epub 2017 Sep 25.

Supplemental Content

Loading ...
Support Center